19-50323685-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The ENST00000477616.2(KCNC3):c.1268G>A(p.Arg423His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/20 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R423C) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000477616.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KCNC3 | NM_004977.3 | c.1268G>A | p.Arg423His | missense_variant | 2/5 | ENST00000477616.2 | NP_004968.2 | |
KCNC3 | NM_001372305.1 | c.1040G>A | p.Arg347His | missense_variant | 2/5 | NP_001359234.1 | ||
KCNC3 | NR_110912.2 | n.69-2901G>A | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KCNC3 | ENST00000477616.2 | c.1268G>A | p.Arg423His | missense_variant | 2/5 | 1 | NM_004977.3 | ENSP00000434241 | ||
KCNC3 | ENST00000670667.1 | c.1268G>A | p.Arg423His | missense_variant | 2/4 | ENSP00000499301 | P3 | |||
KCNC3 | ENST00000376959.6 | c.1268G>A | p.Arg423His | missense_variant | 2/5 | 5 | ENSP00000366158 | A2 | ||
KCNC3 | ENST00000474951.1 | c.-74-2901G>A | intron_variant | 2 | ENSP00000432438 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Spinocerebellar ataxia type 13 Pathogenic:10
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, Clinical Exome/Genome Diagnostics Group, University Hospital Bonn | Aug 05, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | Feb 14, 2023 | The missense c.1268G>A(p.Arg423His) variant in KCNC3 gene has been reported in heterozygous state in multiple individuals affected with KCNC3 related disorders (Khare S, et. al., 2017; Coutelier M, et. al., 2017; Duarri A, et. al., 2015). Functional studies show p.Arg423His disrupts the channel activity of the KCNC3 protein and demonstrates a dominant-negative effect (Figueroa KP, et. al., 2010). The p.Arg423His variant is novel (not in any individuals) in gnomAD Exomes and 1000 Genomes. This variant has been reported to the ClinVar database as Pathogenic (multiple submissions). The amino acid change p.Arg423His in KCNC3 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Arg at position 423 is changed to a His changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Feb 02, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0103 - Dominant negative and gain of function are known mechanisms of disease in this gene and are associated with Spinocerebellar ataxia 13 (MIM#605259). (PMIDs: 22289912, 26442672, GeneReviews). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity. Age of onset (congenital or adult-onset), phenotype and disease progression depend on the location of the variant and its action on the channel, Kv3.3. (PMID: 25756792; 26442672, GeneReviews). (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to histidine. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools. Very high conservation with a minor amino acid change. (SP) 0600 - Variant is located in the annotated transmembrane S4 domain (UniProt, PMID: 26442672). (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported as pathogenic in multiple individuals with early onset non-progressive spinocerebellar ataxia. It has been shown to segregate with disease in several families, and there have been at least two reports of de novo cases (ClinVar, LOVD3, PMID: 19953606, 21479265, 25756792, 28467418). (SP) 0902 - This variant has moderate evidence for segregation with disease (PMID: 28467418). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Targeted expression in zebrafish and drosophila models have demonstrated disrupted axonal pathfinding and neurodegeneration consistent with the neurodevelopmental presentations of disease in patients (PMIDs: 21543613, 30862666, 28467418). In addition, patch clamp studies of this variant expressed in Xenopus oocytes have shown significant loss of Kv3.3 channel activity, reduced current amplitude and cell surface expression. (PMIDs: 19953606, 22289912, 25756792). NB. However, patch clamp assays have been shown to be unreliable; therefore results from these studies are used with caution during variant classification. (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Nov 15, 2018 | - - |
Pathogenic, no assertion criteria provided | research | O&I group, Department of Genetics, University Medical Center of Groningen | Jul 22, 2021 | - - |
Pathogenic, criteria provided, single submitter | research | Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Fondazione Stella Maris | Jan 04, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Oct 30, 2020 | This sequence change is predicted to replace arginine with histidine at codon 423 of the KCNC3 protein (p.(Arg423His)). The arginine residue is invariant across species (100 vertebrates, UCSC), and is located in the S4 transmembrane segment in the ion transport domain. There is a small physicochemical difference between arginine and histidine. The variant is absent in a large population cohort (rs797044872, gnomAD v2.1 and v3.0). This variant has been identified in multiple individuals with early-onset non-progressive spinocerebellar ataxia, with at least two individuals assumed de novo (PMID: 19953606 , 25756792, 28216058, 28467418). The variant segregates with affected status in multiple families (PMID: 19953606, 28216058, 28467418). A zebrafish model of the variant recapitulates the cerebellar degeneration, and demonstrated differential affects on Purkinje cell excitability, maturation, and viability to an adult-onset associated variant (PMID: 32644043). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (5/5 algorithms). Based on the classification scheme RMH Modified ACMG Guidelines v1.3.0, this variant is classified as PATHOGENIC. Following criteria are met: PS3, PM6_Strong, PP1_Strong, PS4_Moderate, PM2_Supporting, PP3. - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is not observed in the gnomAD v2.1.1 dataset. Missense changes are a common disease-causing mechanism. Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID:19953606, 22289912, 25756792, 28467418). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.92; 3Cnet: 0.72). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000208671). The variant has been previously reported as de novo (PMID: 28467418). and observed in multiple (>3) similarly affected unrelated individuals (PMID:19953606, 28467418). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | Oct 08, 2014 | - - |
not provided Pathogenic:9
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Apr 04, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 04, 2023 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 423 of the KCNC3 protein (p.Arg423His). For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects KCNC3 function (PMID: 19953606, 22289912, 25756792, 28467418). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt KCNC3 protein function. ClinVar contains an entry for this variant (Variation ID: 208671). This missense change has been observed in individual(s) with spinocerebellar ataxia (PMID: 19953606, 25756792, 28467418). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Feb 20, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 17, 2021 | DNA sequence analysis of the KCNC3 gene demonstrated a sequence change, c.1268G>A, in exon 2 that results in an amino acid change, p.Arg423His. This sequence change is absent in the gnomAD population database. This sequence change has been previously described in individuals and families with ataxia or spinocerebellar ataxia 13 (PMIDs: 19953606, 25756792, 28467418, 28216058). The p.Arg423His change affects a highly conserved amino acid residue located in the S4 transmembrane segment of the KCNC3 protein. It appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Functional studies show p.Arg423His disrupts the channel activity of the KCNC3 protein and demonstrates a dominant-negative effect (PMIDs: 19953606, 25756792, 28467418). These collective evidences suggest this p.Arg423His change is pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Sep 15, 2021 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 10, 2022 | Published functional studies demonstrate a damaging effect, resulting in loss of channel activity consistent with a strong dominant negative effect (Figueroa et al., 2010; Duarri et al., 2015); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25356970, 23734863, 22289912, 19953606, 26795593, 21479265, 28216058, 28467418, 25756792, 33624863) - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 16, 2021 | The c.1268G>A (p.R423H) alteration is located in exon 2 (coding exon 2) of the KCNC3 gene. This alteration results from a G to A substitution at nucleotide position 1268, causing the arginine (R) at amino acid position 423 to be replaced by a histidine (H). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration has been reported in multiple unrelated patients with early-onset slowly-progressive ataxia (Figueroa, 2010; Duarri, 2015; Khare, 2017). This amino acid position is highly conserved in available vertebrate species. The p.R423H alteration has been shown in multiple independent studies to negatively affect Kv3.3 channel functioning by suppressing current amplitude (Figueroa, 2010), significantly altering gating (Minassian, 2012), or resulting in altered glycosylation and aberrant retention of the mutant channels in the anterograde and/or endosomal vesicles instead of at the plasma membrane (Khare, 2017). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at